Adult Vaccine Market Global Forecast Report by Disease wise (Influenza, Cervical Cancer, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, Tdap, Travel and Miscellaneous, Varicella) Countries and Company Analysis, 2024-2032

Adult Vaccine Market Analysis

The global adult vaccine market was valued at US$ 20. 59 billion in 2023 and is projected to reach US$ 35.87 billion by 2032 with the compound annual growth rate of 6.36% from 2024 to 2032. The human life span is stretching now than ever before, therefore making adult vaccination a critical measure in controlling spread of infectious diseases. A shift in the demography of a population and awareness to preventive measures of health have raised the frequency of adult immunization.

What is an Adult Vaccine?

Adult vaccines are vaccines which are specifically developed for those above the age of 18 years for the purpose of preventing invasive infections. While some of the vaccines are administered during childhood ones are administered to adults depending on their age, life style, health status, travel, and occupation. Such vaccines are used in the prevention of Influenza, pneumonia, hepatitis, shingles, and soon. The first vaccines are those which every individual need for one or another reason, for keeping the immunity raised, such as the tetanus booster, meanwhile there are vaccines which protect the population against new kinds of threats. Because immunity may decline after some time, adult immunization is important in establishing long steady and strong health, especially in the elderly or persons with underlying chronic diseases that give a severe disease. Annual, vaccines could have prevented the deaths of many adults in different parts of the world and greatly affected the world's healthcare systems financially. Vaccine-preventable respiratory diseases like influenza and pneumococcal disease cost the global community more that 23 million years of life due to premature mortality.

Global Use and Significance

Adult vaccines have been widely utilized in the global community owing to increased consciousness of vaccine preventable diseases, increasing population of the aging persons and improvement on public health measures. High levels of vaccination are witnessed among developed nations in North America and Europe; healthcare is well developed and immunizations supported by government. But there is a shift towards advocate for improved uptake of adult vaccines in the emerging markets where knowledge and availability of vaccines are relatively low. Adult immunizations' goal is to improve the health outcomes of people around the world through vaccine-preventable diseases among adults Ergo they are part of herd immunity, hence curtailing diseases transmission among people curtailing the burden on the health systems.

Growth Factors in the Adult Vaccine Industry

Increasing Awareness of Preventive Healthcare

Increased population of the seniors across the globe is a key driver to the growth of the adult vaccine market. People in their old age become more vulnerable to infections and several other complications due to the deterioration of the immune system. Use of specific vaccines such as the 'adult' vaccines including those meant for respiratory conditions for instance, flu as well as pneumonia has been on the rise among geriatric patients. The global increase of chronic diseases like, heart disease diabetes, respiratory diseases make it desirable for the vulnerable groups to be vaccinated. One of the main market drivers is the continually increasing number of people of aging population worldwide and the need for comprehensive programs of adult immunization and special vaccines.

Aging Population and Chronic Disease Prevalence

The rising global population of older adults is a significant growth factor for the adult vaccine market. As people age, their immune systems weaken, making them more susceptible to infectious diseases and complications. Vaccines tailored to adults, especially those targeting respiratory illnesses like flu and pneumonia, are increasingly in demand among the elderly. The prevalence of global chronic conditions such as heart disease, diabetes, and respiratory disorders heightens the need for vaccination in these vulnerable groups. As the aging population expands worldwide, the demand for effective adult immunization programs and tailored vaccines is expected to fuel industry growth.

Government Support: A Pillar of the Adult Vaccine Market

The most important factors affecting the adult vaccines market include government policies /immunization programs. Most of the countries are either administrating or planning to continue a national immunization program that incorporates adult vaccines, especially in the developing countries where the population aging rate is rapidly rising. Ones the vaccines are available in the market there are some incentives provided by public health organizations and government in way of subsidies and awareness and also through free or low-cost vaccination to increase coverage rates. Other organizations such as the WHO and the CDC also help in recommending and encouraging adult vaccines. They collectively provide a substantial boost to the market growth by making it easier and inviting more and more people to take adult vaccinations.

Asia Pacific: A Key Player in the Adult Vaccine Market

They are demonstrated to be part of the Asia Pacific region that has solidified as a promising market for the adult vaccines, with several countries intensifying their efforts towards healthcare security, and diversification of industry. It has been characterized by an explosive growth of the market. The country called the 'pharmacy of the world' was sending out COVID-19 vaccines to other countries up to May 2022 distributing more than the 60 percent of the global demand for vaccines. They have, both domestic and foreign, triggered a production increase. South Korea and Singapore alone have secured more than $3 billion in the past two years explicitly for vaccines, their research and manufacturing plants.

Global COVID-19 vaccine availability and distribution in 2022 showed that nations are significant to one another in terms of vaccine availability. Australia that has been striving to enhance domestic capacities for production imported over 70 million doses. On the other hand, capitalizing on their manufacturing prowess, India and China supplied 900 million and 750 million doses mainly to Africans and Latin Americas. For example, in the case of the China-ASEAN Free Trade Agreement, the dynamism in trade in biotech products including vaccines has also been realized. Given that the governments in Asia Pacific countries and the private players have made such investment in the preventive vaccines, the trends show a rosy picture for the preventive vaccines market in the near future.

Adult Vaccine Market Company Overview

The global adult vaccine market features prominent players such as GlaxoSmithKline, plc., AstraZeneca plc, Sanofi Pasteur, Pfizer, Inc., and CSL Limited. These industry leaders actively develop and distribute vaccines for the adult population globally.

Adult Vaccine Market News

In April 2024, Merck's Phase 3 trial STRIDE-10 results were released at the 34th ESCMID Global in Barcelona, Spain. The trial evaluated Merck's adult-specific 21-valent pneumococcal conjugate vaccination, V116, compared to PPSV23 in people 50 and older who had not received a pneumococcal vaccination before.

In August 2022, Pfizer-BioNTech COVID-19 mRNA vaccine is safe and effective, according to the WHO Strategic Advisory Group of Experts on Immunization (SAGE).

Disease Wise - Market breakup in 10 viewpoints:

1. Influenza

2. Cervical Cancer (HPV)

3. Zoster (Shingles)

4. MMR (Measles, Mumps, and Rubella Vaccine)

5. Pneumococcal

6. Meningococcal

7. Hepatitis

8. TdaP

9. Travel and Miscellaneous

10. Varicella

Country - Market breakup in 21 viewpoints:

North America

United States

Canada

Europe

United Kingdom

Germany

France

Russia

Italy

Spain

Switzerland

Asia Pacific

India

China

Japan

Australia

South Korea

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

Saudi Arabia

United Arab Emirates

South Africa

Rest of the World

All the Key players have been covered from 5 Viewpoints:

• Overviews
• Key Person
• Recent Developments & Strategies
• Product Portfolio & Product Launch in Last 1 Year
• Revenue

Company Analysis:

1. GlaxoSmithKline, plc.

2. AstraZeneca plc

3. Sanofi Pasteur

4. Pfizer, Inc.

5. CSL Limited